865-299-6250 info@edpbiotech.com

San Francisco, California, Sept. 23, 2019 (GLOBE NEWSWIRE) — US Capital Global has advised on a $5 million preferred equity facility for privately held medical device company, EDP Biotech Corporation (“EDP Biotech”), headquartered in Knoxville, TN. EDP Biotech is in the process of developing and launching its first commercial product, ColoPlex™, a new biomarker assay to be used in the early detection of colorectal cancer.

Headquartered in San Francisco, US Capital Global is a full-service private financial group with an established track record in investment banking, asset management, investment management, and capital formation services. The group’s registered broker-dealer affiliate, US Capital Global Securities, LLC, acted as the exclusive placement agent for the equity placement for EDP Biotech earlier this year.

“We are thankful to have had US Capital Global Securities’ experienced team assist us by providing financial advisory services and by raising an initial part of this Series A round of funding,” said Eric Mayer, CEO at EDP Biotech. “This supports our objective of launching ColoPlex™ in the European market.”

“It has been a pleasure to serve EDP Biotech as its lead financial advisor,” said Charles Towle, Managing Partner at US Capital Global and CEO at US Capital Global Securities. “EDP Biotech has strategic plans to advance its market expansion into the rapidly growing medical device sector. Our shared enthusiasm for the company’s unique product was a key determinant in accepting this engagement.”